OCULAR THERAPEUTIX INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Leslie J. Williams

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Leslie J. Williams”): 101,077,347 for, 10,146,298 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Seung Suh Hong, Ph.D., Richard L. Lindstrom, M.D. and Leslie J. Williams as Class II directors to serve until the 2028 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 17,956,526 for, 483,450 withheld, 4,845,607 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Richard L. Lindstrom, M.D.

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Richard L. Lindstrom, M.D.”): 89,771,755 for, 21,451,890 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Seung Suh Hong, Ph.D., Richard L. Lindstrom, M.D. and Leslie J. Williams as Class II directors to serve until the 2028 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 16,929,679 for, 1,455,096 withheld, 4,900,808 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Seung Suh Hong, Ph.D.

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Seung Suh Hong, Ph.D.”): 100,220,435 for, 11,003,210 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Seung Suh Hong, Ph.D., Richard L. Lindstrom, M.D. and Leslie J. Williams as Class II directors to serve until the 2028 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 22,348,257 for, 882,125 withheld, 55,201 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT OF OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO PROVIDE FOR OFFICER EXCULPATION.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(5) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to provide for officer exculpation.”): 105,375,347 for, 5,774,801 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to provide for officer exculpation.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 22,709,197 for, 560,724 against, 15,762 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 8,750,000 shares.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(3) The Company's stockholders approved Amendment No. 4 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 8,750,000 shares.”): 88,785,389 for, 22,350,444 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) The Company's stockholders approved Amendment No. 4 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 8,750,000 shares.”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 17,695,911 for, 5,573,910 against, 15,762 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 329,170 for.

Description as filed by funds: To approve an amendment and restatement of the Ocular Therapeutix, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares of common stock issuable thereunder by 2,000,000 shares and to remove the annual "evergreen" provision.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(4) The Company's stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan to increase the number of shares of common stock of the Company issuable thereunder by 2,000,000 shares and to remove the”): 107,048,833 for, 4,117,635 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) The Company's stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan to increase the number of shares of common stock of the Company issuable thereunder by 2,000,000 shares and to remove the annual "evergreen"”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 23,269,821 for, 15,762 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 2 managers: 328,149 for.

Description as filed by funds: To approve an advisory vote on named executive officer compensation.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”): 83,186,516 for, 27,851,866 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 14,455,497 for, 8,814,324 against, 15,762 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 154 managers: 60,094,874 for, 19,806,501 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2025.

OCULAR THERAPEUTIX INC.’s own tally for this item (“(6) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 139,215,385 for, 3,425,804 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(6) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 23,268,361 for, 1,560 against, 15,762 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.